The University of Texas System

John V Heymach

Monique Nilsson

Jacqulyne Robichaux

Philip Jones

Jason Cross

Jay Theroff

Lauren A Byers

Carl M Gay

Provided herein are methods for determining a subtype of a small cell lung cancer in a patient based on the express status of ASCL1, NEUROD1, and POU2F3, which are expressed in a mutually exclusive fashion. The subtype of the cancer can be used to determine the sensitivity of the cancer to certain anti-cancer therapies. As such, also provided are methods of treating patients having small cell lung cancer based on the subtyping results.

Molecular subtyping of small cell lung cancer to predict therapeutic responses

The present disclosure provides methods of treating cancer in a patient determined to have an EGFR and/or HER2 exon 20 mutation, such as an insertion mutation, by administering a third-generation tyrosine kinase inhibitor, such as poziotinib or afatinib.

Compounds with anti-tumor activity against cancer cells bearing EGFR or HER2 exon 20 mutations

The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of HER2 or EGFR for the treatment or prevention of disease, including cancer.

Heterocyclic inhibitors of tyrosine kinase

Growing community of inventors

Houston, TX, United States of America

John V Heymach